No Data
ADRs Close Lower; Renalytix Declines 29%
This article was automatically generated by MarketWatch using technology from Automated Insights. International stocks trading in New York closed lower on Wednesday, as the S&P/BNY Mellon index of Am
Renalytix to Appeal Nasdaq Delisting Over Non-compliance
Renalytix (2O9.F) plans to appeal the Nasdaq Stock Market's decision to delist the company for non-compliance with listing requirements, according to a Tuesday release. The AI-based in-vitro diagnosti
Form 8.5 (EPT/RI)-Renalytix Plc
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.
Renalytix Shares Are Trading Higher After the Company Announced Medicare Issued a Final Local Coverage Determination for Its KidneyintelX.dkd Testing
Renalytix Shares Are Trading Higher After the Company Announced Medicare Issued a Final Local Coverage Determination for Its KidneyintelX.dkd Testing
Renalytix's Diabetes, Kidney Disease Test Gets Medicare Final Coverage Determination
Renalytix (RENX.L) said Friday that Medicare issued a final local coverage determination for its kidneyintelX.dkd prognostic test, with the price set at $950 per test.
Medicare Issues Final Coverage Determination for KidneyintelX.dkd
LONDON and NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) announces that on June 13, 2024 Medicare issued a final Local Coverage Determination ("LCD") for the Company's